• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency

    Thumbnail
    View/Open
    Nghiem211105.pdf (921.4Kb)
    Author(s)
    Windegger, Tanja M
    Nghiem, Son
    Kim-Huong, Nguyen
    Fung, Yoke-Lin
    Scuffham, Paul A
    Griffith University Author(s)
    Scuffham, Paul A.
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    Background and Objective Immunoglobulin replacement therapy (IRT) is often used to support patients with primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID). Home‐based subcutaneous immunoglobulin (SCIg) is reported to be a cheaper and more efficient option compared to hospital‐based intravenous immunoglobulin (IVIg) for PID. In contrast, there is little information on the cost‐effectiveness of IRT in SID. However, patients who develop hypogammaglobulinaemia secondary to other conditions (SID) have different clinical aetiology compared to PID. This study assesses whether SCIg provides a good ...
    View more >
    Background and Objective Immunoglobulin replacement therapy (IRT) is often used to support patients with primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID). Home‐based subcutaneous immunoglobulin (SCIg) is reported to be a cheaper and more efficient option compared to hospital‐based intravenous immunoglobulin (IVIg) for PID. In contrast, there is little information on the cost‐effectiveness of IRT in SID. However, patients who develop hypogammaglobulinaemia secondary to other conditions (SID) have different clinical aetiology compared to PID. This study assesses whether SCIg provides a good value‐for‐money treatment option in patients with secondary immunodeficiency disease (SID). Methods A Markov cohort simulation model with six health states was used to compare cost‐effectiveness of IVIg with SCIg from a healthcare system perspective. The costs of treatment, infection and quality‐adjusted life years (QALYs) for IVIg and SCIg treatment options were modelled with a time horizon of 10 years and weekly cycles. Deterministic and probabilistic sensitivity analyses were performed around key parameters. Results The cumulative cost for IVIg was A$151 511 and for SCIg A$144 296. The QALYs with IVIg were 3·07 and with SCIg 3·51. Based on the means, SCIg is the dominant strategy with better outcomes and at lower cost. The probabilistic sensitivity analysis shows that 88·3% of the 50 000 iterations fall below the nominated willingness to pay threshold of A$50 000 per QALY. Therefore, SCIg is a cost‐effective treatment option. Conclusion For SID patients in Queensland (Australia), the home‐based SCIg treatment option provides better health outcomes and cost savings.
    View less >
    Journal Title
    VOX SANGUINIS
    Volume
    114
    Issue
    3
    DOI
    https://doi.org/10.1111/vox.12760
    Copyright Statement
    © 2019 International Society of Blood Transfusion. This is the peer reviewed version of the following article: Cost–utility analysis comparing hospital‐based intravenous immunoglobulin with home‐based subcutaneous immunoglobulin in patients with secondary immunodeficiency, Vox Sanguinis, Vol. 114, 237–246, 2019, which has been published in final form at 10.1111/vox.12760. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
    Subject
    Clinical sciences
    Medical physiology
    Publication URI
    http://hdl.handle.net/10072/384677
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander